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Mitral Surgical Prosthetic Dysfunction
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MaBioprosthetic valve use has increased signiﬁcantly. Considering their limited durability, there will remain an ongoing
clinical need for repairing or replacing these prostheses in the future. The current standard of care for treating
bioprosthetic valve degeneration involves redo open-heart surgery. However, repeat cardiac surgery may be associated
with signiﬁcant morbidity and mortality. With the rapid evolution of transcatheter heart valve therapies, the feasibility
and safety of implanting a transcatheter heart valve within a failed tissue valve has been established. We review the
historical perspective of transcatheter valve-in-valve therapy, as well as the main procedural challenges and clinical
outcomes associated with this new less invasive treatment option. (J Am Coll Cardiol 2015;66:2019–37) © 2015 by the
American College of Cardiology Foundation.A pproximately 85,000 heart valve prosthesesare implanted in the United States eachyear, and a total of 275,000 worldwide (1).
There are 2 main types of heart valve prostheses: 1)
mechanical prosthetic valves, which require lifelong
anticoagulation; and 2) tissue valves, which obviate
the need for anticoagulation, but do not last as long
as their mechanical counterparts. In the United
States, the use of bioprosthetic aortic valve replace-
ment increased from 26.7% in 1998 to 50.2% in 2005
(1,2). This major shift in the use of surgical bio-
prostheses, combined with their shorter durability
and the increasing life expectancy of an aging popula-
tion, is expected to translate into a major increase in
the incidence of patients with surgical valve failure in
the coming years.
The standard of care for degenerated bioprosthetic
valves currently involves reoperative valve replace-
ment. Over the last 2 decades, the mortality associated
with redo aortic valve surgery has decreased signiﬁ-
cantly (3–5). Nevertheless, depending on risk factorsm the Quebec Heart & Lung Institute, Laval University, Quebec City, Que
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Advanced age, female sex, preoperative New York
Heart Association functional class, left ventricular
dysfunction, renal failure, pulmonary disease, cogni-
tive impairment, number of prior operations, urgency
of operation, and technical difﬁculties caused by
adhesions have each been identiﬁed as predictors of
higher reoperative risk (4,5,7).
Transcatheter aortic valve replacement (TAVR) is
now established as the preferred treatment option for
inoperable patients and a valid alternative for high-
risk individuals with severe symptomatic native
aortic stenosis (8). In recent years, following rapid
evolution within the transcatheter valve ﬁeld, the
successful placement of new bioprosthetic valves via
a transcatheter approach within degenerative aortic,
mitral, tricuspid, and pulmonic surgical bioprostheses
has been conﬁrmed (9–13). This study reviews the
historical perspective, technical challenges, majorbec, Canada. Dr. Rodés-Cabau has received research
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valve
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2020risks, and outcomes associated with trans-
catheter valve-in-valve procedures in pa-
tients with failed left-sided (aortic and mitral)
surgical bioprostheses.
SURGICAL BIOPROSTHETIC VALVES
Characteristics of the main surgical bio-
prostheses are summarized in Table 1. Sur-
gical bioprostheses are usually made of
leaﬂets from bovine pericardium or porcine
valve leaﬂets. Homografts, which are less
frequently used, are composed of human
tissue. Bioprosthetic valves can be further
categorized as stented or stentless. The 3
main components of stented bioprosthetic
valves are: 1) valve leaﬂets, which can be
mounted internally or externally; 2) the stentframe, which is composed of polymeric material or
alloys; and 3) a circular or scallop-shaped external
sewing ring (Figure 1) (7). Surgical heart valves are
manufactured as either intra-annular or supra-
annular, and the portion visible on ﬂuoroscopy can
be either the stent frame or the sewing ring. The
sewing ring is located at the bottom or 3 to 5 mm above
the bottom of the stent frame in the supra- and intra-
annular valve designs, respectively (14).
Stentless valves were developed to optimize the
effective oriﬁce area and thus facilitate left ventric-
ular mass regression (15). These valves do not have a
base ring or a frame to support the leaﬂets, are su-
tured to the root in the actual position of the native
valve, and can be of autograft, heterograft, or homo-
graft origin (15,16).
More recently, sutureless valves that avoid the
placement of sutures following annulus decalciﬁca-
tion have been introduced, with the objective of
reducing cross-clamp and cardiopulmonary bypass
duration, and facilitating minimally invasive surgery
and complex cardiac interventions (17).
LABELING OF SURGICAL BIOPROSTHETIC VALVES. Sur-
gical heart valve (SHV) sizing across manufacturers
lacks standardization (18). This may lead to confusion
because the valve size labeling may correspond to
internal or external diameters for stented valves, and
to external diameter for stentless valves (7). Conse-
quently, 2 bioprostheses may have distinctive inter-
nal and external sewing ring diameters, despite
having the same label size. For valve-in-valve ther-
apy, the most relevant parameter relates to valve in-
ternal dimensions, which are often signiﬁcantly
smaller than the labeled valve size. Therefore, when
envisioning a valve-in-valve procedure, it is impera-
tive for the heart team to elicit the precise diametersof the failing bioprosthetic valve (usually available by
reviewing published detailed tables providing valves
dimensions (7,19) or by consulting directly with the
manufacturer). However, it is important to realize
that, by convention, the stent internal diameter rep-
resents exclusively the internal dimension of a bare
stent covered with fabric or pericardium, without
accounting for the effect of artiﬁcial leaﬂets sutured
within the stent (20). Indeed, in a study conceived to
assess the effect of tissue leaﬂets on stent internal
diameter, the true internal valve diameter was
smaller than the actual stent internal diameter in the
majority of SHV designs (20). Moreover, calciﬁcation
or pannus can generate a discrepancy between the
expected and the observed internal stent diameters.
Multidetector computed tomography (MDCT) and
transesophageal echocardiography could be per-
formed to determine the precise dimensions of the
SHV. Nevertheless, considering the absence of stan-
dardized measures regarding the internal diameter of
a variety of SHVs and the variability of the measure-
ments obtained from differing imaging modalities,
the exact role of pre-procedural imaging with MDCT
or transesophageal echocardiogram (TEE) in the
valve-in-valve ﬁeld is yet to be determined.
FAILURE OF BIOPROSTHETIC VALVES: MECHANISMS
AND INCIDENCE. Structural dysfunction, due to pro-
gressive tissue deterioration, is the main cause of
bioprosthetic valve failure. The major pathophy-
siological mechanism underlying this process is cusp
calciﬁcation. This mineralization process may
engender pure stenosis via cusp stiffening, and may
also precipitate regurgitation due to secondary tears.
Recent studies have suggested that bioprosthetic
valve calciﬁcation is an active rather than a passive
process, and is modulated by numerous mechanisms,
including lipid-mediated inﬂammation, immune
response, and dysfunctional phosphocalciﬁc meta-
bolism (21). Calcium deposits can be located on cuspal
tissue (intrinsic calciﬁcation), but may also develop in
thrombi or endocarditic vegetations (extrinsic calci-
ﬁcation) (1). To attenuate calciﬁcation and further
degeneration, glutaraldehyde valve leaﬂet pretreat-
ment is widely used.
Another mechanism contributing to the limited
lifespan of bioprosthetic valves is progressive collagen
deterioration (1). Design-related tearing, rather than
leaﬂet calciﬁcation, generally explains the deteriora-
tion of bovine pericardial valves (1). The formation of
tissue overgrowth (e.g., pannus), thrombus, or para-
valvular leaks can usually explain bioprosthesis
dysfunction not related to leaﬂet failure. Usually,
valve stenosis is the consequence of calciﬁcation,
pannus, or thrombus, whereas leaﬂet destruction or
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2021paravalvular leak will lead to regurgitation. The
outcome of the degenerative tissue valves can also be
a combination of stenosis and regurgitation.
The mechanisms of aortic bioprosthetic dysfunc-
tion are equally distributed as predominantly ste-
notic, regurgitant, or mixed, with a higher rate of
stenotic dysfunction among stented and smaller
(#21 mm) valves, and a predominant regurgitant
mechanism among stentless valves (11). In mitral
bioprostheses, regurgitation is the predominant
mechanism of valve dysfunction (49%), followed
by stenosis (21%) and combined mechanisms
(30%) (22).
The incidence of aortic and mitral bioprosthesis
structural valve deterioration (SVD) requiring rein-
tervention is 20% to 30% at 10 years and over 50% at
15 years (23,24) (Central Illustration). Because bio-
prosthetic valve calciﬁcation is hastened in younger
individuals, the likelihood of primary tissue failure
diminishes with age (1,25,26) (Figure 2). Sénage et al.
(27) showed that early valve failure is not infre-
quent and constitutes a life-threatening condition. A
younger age at implantation, renal failure, hyper-
parathyroidism, higher post-operative gradients,
prosthesis-patient mismatch (PPM), and mitral valve
position are associated with a higher risk of tissue
valve deterioration (21,23,24,26). One of the most
likely hypotheses for the greater frequency of mitral
bioprosthetic failure relative to aortic bioprosthetic
failure may be partially related to the higher close-
off pressure in the mitral position (usually >100
mm Hg vs. <100 mm Hg in the aortic position). Also,
the closure time is expected to be greater with a
mitral prosthesis compared with an aortic pros-
thesis, possibly contributing to a higher degenera-
tion rate (1).
TRANSCATHETER VALVE-IN-VALVE
INTERVENTIONS: HISTORICAL PERSPECTIVES
AORTIC POSITION. Following pre-clinical studies
evaluating the valve-in-valve technique, the ﬁrst-in-
human cases of valve-in-valve procedures for treat-
ing aortic bioprosthetic dysfunction were reported in
2007 using the CoreValve and Cribier-Edwards valve
systems (9,28,29). This was followed by publication of
several case reports of valve-in-valve procedures
combining different transcatheter devices (30–35) and
surgical valves, as well as several small single-center
and multicenter series (36–39). More recently, retro-
spective collection of valve-in-valve cases on a
voluntary basis from different centers worldwide has
led to the publication of the 2 largest series of valve-
in-valve procedures to date, including 202 and 459patients, respectively (10,11). In addition, a prospec-
tive registry evaluating the Edwards SAPIEN valve
for valve-in-valve procedures has recently been
completed (PARTNER VinV registry [PARTNER II
Trial: Placement of AoRTic TraNscathetER Valves];
NCT01314313) and another prospective registry
using the CoreValve system (Medtronic) is still
ongoing (Safety and Efﬁcacy Study of the Medtronic
CoreValve System in the Treatment of Symptomatic
Severe Aortic Stenosis With Signiﬁcant Comorbidities
in Very High Risk Subjects Who Need Aortic Valve
Replacement; NCT01675440).
To date, the vast majority of valve-in-valve pro-
cedures for aortic valve dysfunction have been per-
formed with the Edwards SAPIEN/SAPIEN XT valves
(Edwards Lifesciences, Irvine, California) and the
CoreValve system (Medtronic, Minneapolis, Minne-
sota). Nonetheless, most transcatheter valves avail-
able for the treatment of native aortic valve stenosis
have also been used for treating surgical aortic bio-
prosthetic dysfunction (Figure 3).
MITRAL POSITION. Data from pre-clinical studies
proving the concept of mitral valve-in-valve and
valve-in-ring procedures were reported in 2007 (9)
and 2009 (40), respectively. The ﬁrst-in-human
cases of valve-in-valve and valve-in-ring procedures
for mitral valve or ring dysfunction were reported in
2009 (41) and 2011 (42), respectively. Most cases of
mitral valve-in-valve or valve-in-ring have been
performed with the balloon-expandable Edwards
system, via transapical or antegrade transfemoral
approaches. The balloon-expandable Melody valve
(Medtronic, Minneapolis, Minnesota) has been used
in a minority of cases (43,44). More recently, the use
of self-expandable transcatheter valve systems for
treating mitral valve dysfunction has also been re-
ported (45) (Figure 3).
AORTIC VALVE-IN-VALVE PROCEDURES
PRE-PROCEDURAL WORK-UP AND PROCEDURAL
ASPECTS. The pre-procedural work-up and peri-
procedural steps involved in valve-in-valve pro-
cedures are similar to those used for patients with
native aortic valve stenosis considered for TAVR (46).
However, speciﬁc aspects of preparation of a valve-
in-valve procedure should be considered:
1. Type of bioprosthesis dysfunction. A sound
knowledge of prior cardiac surgery and failed
bioprosthetic valves is essential. A meticulous
echocardiographic evaluation is very useful for
determining the mode of valve failure. In order to
eliminate endocarditis or paravalvular (rather than
TABLE 1 Main Characteristics of SHVs
Manufacturer Valve Model SHV Image
Leaﬂet
Tissue
Relationship of
Leaﬂets to the
Stent Frame
SHV
Fluoroscopic Image
Neoannulus
Fluoroscopic Image
Stented SHV
Edwards Lifesciences
(Irvine, California)
Carpentier-Edwards
Perimount 2700
Bovine
Pericardium
Inside
Carpentier-Edwards
Perimount
Bovine
Pericardium
Inside
Carpentier-Edwards
Perimount Magna
and Magna ease
Bovine
Pericardium
Inside
Carpentier-Edwards
aortic porcine
bioprosthesis
Porcine Inside
Carpentier-Edwards
supra-annular aortic
porcine bioprosthesis
Porcine Inside
Medtronic (Minneapolis,
Minnesota)
Mosaic Tissue valve Porcine Inside
Hancock II Tissue valve Porcine Inside
St. Jude Medical
(St. Paul, Minnesota)
Epic (Biocor) valve Porcine Inside
Epic Supra
(Biocor Supra)
valve
Porcine Inside
Trifecta Bovine
Pericardium
Outside
Sorin (Milan, Italy) Mitroﬂow Bovine
Pericardium
Outside
Soprano Armonia Bovine
Pericardium
Inside
Vascutek (Inchinnan,
United Kingdom)
Aspire Porcine Inside
Continued on the next page
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TABLE 1 Continued
Manufacturer Valve Model SHV Image
Leaﬂet
Tissue
Relationship of
Leaﬂets to the
Stent Frame
SHV
Fluoroscopic Image
Neoannulus
Fluoroscopic Image
Stentless SHV
Edwards Lifesciences Prima root Porcine root Inside
Medtronic Freestyle root Porcine root Inside
St. Jude Medical Toronto SPV root Porcine root Inside
Sorin Freedom Pericarbon Bovine
Pericardium
Inside
Sutureless SHV
Edwards Lifesciences Intuity Elite Bovine
Pericardium
Inside
Medtronic 3F Enable Equine
Pericardium
Inside
Sorin Perceval S Bovine
Pericardium
Inside
Arbor Surgical
Technologies Inc.
(Irvine,
California)
Trilogy Bovine
Pericardium
Inside
Adapted with permission from Bapat et al. (19), Bapat et al. (55), and Flameng et al. (81).
SHV ¼ surgical heart valve.
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FIGURE 1 Dimensions and Design Characteristics of a Stented Bioprosthetic Valve
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(Left) Carpentier-Edwards Perimount Magna Ease aortic valve (Edwards Lifesciences, Irvine, California). (Middle, Right) Computed tomography images
of the Carpentier-Edwards Perimount Magna Ease aortic valve.
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2024transvalvular) leaks, TEE should be routinely per-
formed in patients with regurgitation as the main
mode of valve failure. For those patients present-
ing predominantly with valve stenosis, a careful
review of prior echocardiographic examinations,
as well as recent changes in clinical status should
be undertaken to differentiate between surgical
valve failure and PPM following surgical aortic
valve replacement (SAVR). This is of particular
importance in those patients with smaller surgical
valves (#21 mm), which are frequently associated
with higher transvalvular gradients and a greater
incidence of moderate-to-severe PPM post-SAVR
(47). At best, a valve-in-valve procedure is ex-
pected to reduce transvalvular gradients to the
values obtained immediately following SAVR,
and this should be taken into account in the
clinical decision-making process for valve-in-valve
procedures.
2. Valve sizing remains a challenging aspect of valve-
in-valve procedures. As previously discussed, a
detailed knowledge of the surgical valve labeling is
essential. Importantly, the true inner diameter of
the surgical valve, which is usually a few millime-
ters smaller than the outer diameter, is used
for sizing purposes. As transcatheter valves are
sutureless devices, ensuring transcatheter valve
ﬁxation and stability greatly depends on the prin-
ciple of relative oversizing of the transcatheter
valve with respect to aortic annulus dimensions.
Whereas signiﬁcant paravalvular regurgitation or
embolization may result from transcatheter valve
undersizing, excessive oversizing can lead toincomplete expansion, incorrect functioning, and/
or higher residual gradients (20). To date, in the
absence of dedicated sizing guidelines for valve-in-
valve procedures, the main principles of sizing
(including the degree of oversizing) used for native
aortic valves are usually applied (48–50). Thus,
performing a 3-dimensional (3D) reconstruction (by
computed tomography [CT] or TEE) of the surgical
prosthesis in order to obtain an additional measure
of the inner diameter and area/perimeter is advis-
able. Three-dimensional TEE, a technique that
can be used intraprocedurally during TAVR and
does not require iodinated contrast, has superior
temporal resolution, provides physiological infor-
mation, and essentially eliminates motion-based
artifacts. Nonetheless, 3D TEE is hampered by
suboptimal lateral resolution in the coronal plane,
which diminishes the ability to measure the blood/
tissue interface in this plane. In contrast, MDCT,
which requires iodinated contrast, typically offers
superior tissue/lumen contrast, but may be limited
by artifacts because of partial volume-averaging
effects (blooming), heart/lung motion, patient
motion, and arrhythmias. Both imaging modal-
ities are user-dependent, and prime image acqui-
sition and analysis are essential for satisfactory
annular assessment. Indeed, echocardiography and
MDCT are often considered complementary imag-
ing modalities.
In addition to those imaging modalities, the use of
the Valve in Valve app is highly recommended. This
free app, developed collaboratively by the technology
CENTRAL ILLUSTRATION Valve-in-Valve: Failure of Bioprosthesis
Valves and Transcatheter Options for High-Risk Patients
50%
(15 yrs)
FAILURE OF AORTIC AND MITRAL BIOPROSTHESIS VALVES
TRANSCATHETER VALVE-IN-VALVE (VIV) or VALVE-IN-RING
(Patients at high or prohibitive surgical risk)
Incidence of bioprosthesis failure (no. of years after surgery)
Preprocedural evaluation
Evaluate type of bioprothesis dysfunction; 
valve size; valve positioning; risk of coronary obstruction; 
risk of left ventricular outflow tract (LVOT) obstruction 
Standard-of-care for suitable patients
Reoperative valve replacement.
High-risk patients considered for less invasive procedures — See below
Transcatheter aortic VIV Transcatheter mitral VIVand valve-in-ring
20-30%
(10 yrs)
Risks
Elevated post-procedural gradient
Coronary obstruction
Unknown durability
Malpositioning
Successful procedure
in 95% of patients
30-day
mortality rate
1-year
mortality rate
8% 15.1%
Risks
LVOT obstruction
Thrombosis
Significant mitral regurgitation
Unknown durability
Malpositioning
Successful procedure
in 95% of patients
30-day
mortality rate
14-month
mortality rate
8.5% 20.5%
Paradis, J-.M. et al. J Am Coll Cardiol. 2015; 66(18):2019–37.
Incidence of bioprosthesis valve dysfunction and transcatheter aortic valve-in-valve and
valve-in-ring as alternative treatments in those patients at high or prohibitive surgical risk.
Aspects of the main pre-procedural evaluation, risks, and results of transcatheter
treatment of aortic and mitral bioprosthesis dysfunction are shown.
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2025company UBQO and Dr. Vinayak Bapat, provides
speciﬁc information according to different clinical
scenarios and is helpful for the preparation of valve-
in-valve procedures.
3. Risk of coronary obstruction. Aortic valve-in-valve
procedures have been associated with an
increased risk of coronary obstruction, especially
in patients with stentless valve dysfunction. In a
large series of coronary obstruction cases post-
TAVR, the risk of coronary obstruction was >2
times more frequent among valve-in-valve pro-
cedures compared with TAVR performed within
native valves (51). The main anatomic factors
associated with a higher risk of coronary obstruc-
tion were low coronary height (<12 mm) and
reduced diameter of the sinus of Valsalva (<30mm).
During valve-in-valve cases, a leaﬂet directly con-
tacting either the coronary ostium, or the aortic root
surrounding the coronary ostium most commonly
generates coronary obstruction. The major predis-
posing condition is the proximity of the coronary
ostium to the projected ﬁnal position of the dis-
placed bioprosthetic leaﬂet after transcatheter
heart valve (THV) placement. Therefore, during the
pre-procedural work-up, it is often useful to
perform aortography to identify patients at risk for
coronary obstruction. This should be done in a
projection perpendicular to both the SHV and the
coronary ostia. Because coronary ostia are typically
located midway between 2 surgical valve posts, a
projection perpendicular to the coronary ostia is
generally attained by perfectly superimposing 2
adjacent posts (1 to 2 technique) (52). Computed
tomography or 3D TEE, by allowing 3D anatomic
assessment, can also be used in the screening pro-
cess for the risk of coronary obstruction. However,
even if these modalities can assess the geometric
axis of the SHV at the level of the coronary artery
ostia and can anatomically deﬁne the distance be-
tween the future THV and the coronary ostia, their
role in predicting this potential life-threatening
complication is still evolving. When a patient is at
high risk of coronary obstruction, the following
options should be contemplated: consider redo
open heart surgery; use of periprocedural general
anesthesia; selection of a smaller or underﬁlled
transcatheter valve; positioning the transcatheter
valve in a lower position with respect to the
SHV; use of a retrievable device (e.g., Evolut-R,
Portico, Lotus); use of a trancatheter valve with
clipping mechanism that grasp SHV leaﬂets (e.g.,
JenaValve, Engager); and placement of a wire
and an undeployed stent within the distal coronarybed, ready to be pulled back and implanted emer-
gently, if needed (52).
4. Need for balloon pre-dilation. The role of balloon
aortic pre-dilation during valve-in-valve pro-
cedures is debatable. Degenerative bioprotheses
FIGURE 2 Rates of Reintervention Over Time in Aortic and
Mitral Surgical Bioprostheses
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(A) Age and probability of explant owing to structural valve deterioration (SVD) of aortic
bioprosthetic surgical heart valves. Patients are grouped according to age range. Adapted
with permission from Johnston et al. (26). (B) Actuarial freedom from explant because of
SVD of bioprosthetic mitral surgical heart valves, stratiﬁed by age groups. Adapted with
permission from Bourguignon et al. (80).
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2026are friable, and the risks of embolization and
stroke or destruction and acute regurgitation with
pre-dilation must be weighed against the possi-
bilities of both difﬁcultly in crossing a severely
stenotic surgical valve and suboptimal expansion
of the THV. Although societal guidelines advise
against using balloon dilation for prosthetic left-
sided heart valves (53,54), balloon pre-dilation is
still performed in about one-fourth of valve-in-
valve cases (11). When a retrograde approach is
selected (e.g., transarterial or transaortic crossing
of an aortic biosprosthesis), cautious pre-dilationwith an undersized balloon may be considered,
especially in the presence of a bulky and severely
calciﬁed stenotic aortic valve. In those cases per-
formed through a transapical approach or in the
presence of regurgitant bioprostheses, pre-dilation
is generally not recommended. In surgical valves
with no ﬂuoroscopic markers or in a Mosaic
valve, balloon pre-dilation could be used to locate
the exact level of the neoannulus and facilitate
transcatheter valve positioning. Finally, balloon
pre-dilation can contribute to the evaluation of the
geometric relationship between the SHV and the
coronary ostia (52).
5. Transcatheter valve positioning. The optimal
placement of a transcatheter valve inside a SHV
can be deﬁned as a placement where the valve is
securely ﬁxed to avoid embolization, with its un-
covered portion remaining above the sewing ring
of the SHV (14). The use of a reference plane, or
“neo-annulus” has been proposed by Bapat et al.
(55) to achieve an optimal placement of THV de-
vices inside a given surgical heart valve (Table 1).
Indeed, irrespective of the valve design, the nar-
rowest portion of all surgical valves is at the level
of its sewing ring, which should be used as a
reference level during valve-in-valve cases (55).
The relationship between the ﬂuoroscopically
visible component of a SHV and the level of the
sewing ring must be well acknowledged to opti-
mize transcatheter valve positioning within any
SHV. Similar to conventional TAVR, ﬁnding a
ﬂuoroscopic coplanar or perpendicular view to the
bioprosthetic annular plane is helpful. This can be
accomplished by ﬁnding a ﬂuoroscopic angulation
where the radiopaque components of the bio-
prosthetic basal ring appear as a straight line or
the radiopaque components of the valve posts
seem to be at the same height (52). The use of TEE
can be very useful for valve positioning in the
absence of surgical valve leaﬂet calciﬁcation, in
the presence of stentless valves, or when the mode
of SHV failure is severe regurgitation. Rapid ven-
tricular pacing and the use of repositionable
self-expanding devices can also be considered
to obtain a perfect depth of implantation. Ideally,
the Edwards SAPIEN XT valve should be implanted
4 to 5 mm below the sewing ring of the SHV,
whereas the CoreValve should be positioned 5 mm
below the neoannular plane (14). Interestingly,
optimal THV positioning within stented SHVs
can usually be obtained with minimal contrast
dye injection, or even without any. Several exam-
ples of aortic valve-in-valve cases are shown in
Figure 4.
FIGURE 3 Transcatheter Valves Used for Valve-in-Valve Procedures
Aortic
+
Mitral
Aortic
only
A B C D E F
G H I J K L
(A) Edwards SAPIEN XT (Edwards Lifesciences, Irvine, California); (B) SAPIEN 3 (Edwards Lifesciences, Irvine, California); (C) Lotus (Boston
Scientiﬁc Inc, Natick, Massachusetts); (D) Inovare valve (Braile Biomedica Inc, São José do Rio Preto, Brazil); (E) Melody (Medtronic, Minne-
apolis, Minnesota); (F) Direct Flow (Direct Flow Medical Inc, Santa Rosa, California); (G) CoreValve (Medtronic, Minneapolis, Minnesota); (H)
Evolut R (Medtronic, Minneapolis, Minnesota); (I) Acurate TA system (Symetis Inc, Écublens, Switzerland); (J) Engager (Medtronic, Minneapolis,
Minnesota); (K) Portico (St. Jude Medical Inc., St. Paul, Minnesota); (L) JenaValve (JenaValve Inc, Munich, Germany). Valves A to F have been
used for both aortic and mitral valve-in-valve procedures. Valves G to L have been used only for aortic valve-in-valve cases.
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2027EARLY OUTCOMES
PROCEDURAL AND 30-DAY OUTCOMES. Baseline
characteristics and outcomes of all published case
series including more than 10 aortic valve-in-valve
procedures are shown in Table 2 (10,34,36,56–66).
The mean age was 78 years, and 58% of patients
were men. The mean logistic EuroSCORE (European
System for Cardiac Operative Risk Evaluation) and
Society of Thoracic Surgeons (STS) score were 31.3%
and 11.3%, respectively, which represented a much
higher risk proﬁle than those reported in most TAVR
within native valve series (8). Most surgical valves
were stented (82% vs. 18% stentless). The selected
routes were transfemoral, transapical, transaxillary,
transaortic, and subclavian in 55%, 41.6%, 2%, 1%,
and 0.3% of patients, respectively.
The transcatheter valve was successfully implan-
ted in 94.7% of patients, and the mean 30-day mor-
tality rate was 8% (Central Illustration). The mean
rate of periprocedural complications was: valve
malpositioning/embolization (12.4%); stroke (1.4%);
pacemaker implantation (7.6%); and coronary ob-
struction (2.2%). Interestingly, although the rate
of coronary obstruction and valve malpositioning
seems to be higher, as compared with TAVR within
native valves, pacemaker implantation rates are
much lower. We hypothesize that the surgical valve
structure may function as a protective factor in such
cases, in addition to a higher (more aortic) implanta-
tion of the THV. The relatively high malpositioningrate may be due to positioning challenges in those
cases with aortic regurgitation as a predominant
mechanism of valve failure, which indeed are
frequently associated with a lower degree of valve
calciﬁcation. Also, the lack of ﬂuoroscopic markers in
some stentless valves can make the ﬁnal positioning
of the transcatheter valve challenging, and this may
translate into a higher rate of valve malpositioning.
VALVE HEMODYNAMICS. The mean transvalvular
gradient after aortic valve-in-valve procedures was
15.5 mm Hg (>10 mm Hg in most patients), which is
higher than the gradients reported following TAVR
within native valves (usually #10 mm Hg) (8,46). The
global rate of severe PPM (deﬁned as an effective
oriﬁce area <0.65 cm2/m2) following aortic valve-in-
valve is 32.1% (Figure 5). That the transcatheter
valves are implanted in a nondistensible structure
and the amount of material occupying the aortic
annulus space (surgical valve þ transcatheter valve)
may partially explain such results. In addition, some
patients already presented with elevated gradients
and moderate-to-severe PPM following SAVR
(particularly in the group of smaller surgical valves)
(47), and this also contributes to the high rate of
elevated transvalvular gradients following valve-in-
valve procedures.
Dvir et al. (10) evaluated the factors associated
with higher transvalvular gradients following
valve-in-valve procedures. The use of a balloon-
expandable valve (particularly in those patients with
surgical valves #23 mm) and stenosis (instead of
FIGURE 4 Examples of Aortic Valve-in-Valve Cases
(A) Pre-procedural ﬂuoroscopic image of a failing 21-mm Sorin Mitroﬂow surgical heart
valve (SHV) (Sorin, Milan, Italy). (B) Final position of a 23-mm CoreValve EvolutR (Med-
tronic, Minneapolis, Minnesota) implanted via transfemoral approach. (C) Pre-procedural
ﬂuoroscopic image of a degenerated 23-mm Sorin Mitroﬂow. (D) Final position of a 23-mm
SAPIEN XT (Edwards Lifesciences, Irvine, California) implanted within the SHV through a
transfemoral approach. (E) Fluoroscopic image of a degenerated 27-mm Carpentier-
Edwards Magna (Edwards Lifesciences, Irvine, California). (F) Post-procedural ﬂuoroscopic
image showing a 29-mm St. Jude Portico (St. Jude Medical Inc, St. Paul, Minnesota) inside
the failing SHV. (G) Pre-procedural aortogram showing a failing stentless 23-mm Medtronic
Freestyle valve with severe aortic regurgitation. (H) Post-procedural aortogram showing
the ﬁnal position of the 23 mm SAPIEN XT transcatheter heart valve inside the stentless
SHV. Note the absence of aortic regurgitation.
Paradis et al. J A C C V O L . 6 6 , N O . 1 8 , 2 0 1 5
Valve-in-Valve and Bioprosthetic Valve Dysfunction N O V E M B E R 3 , 2 0 1 5 : 2 0 1 9 – 3 7
2028regurgitation) as a mechanism of surgical valve
dysfunction were the factors associated with higher
transvalvular gradients post-TAVR (Figure 6). In those
patients receiving a CoreValve, a depth of implanta-
tion >6 mm below the surgical valve was also asso-
ciated with higher residual gradients.
The mean rate of paravalvular leaks of at least
moderate degree following valve-in-valve procedures
is 4%, much lower than the w10% to 12% reported
with ﬁrst-generation transcatheter valves (8). In fact,
up to 74% of the patients had none or trace residual
leak following a valve-in-valve procedure, which is
similar to the results obtained with the last genera-
tion of transcatheter valves for treating native aortic
stenosis.
There are some major differential aspects between
conventional TAVR and valve-in-valve procedures.
Table 3 condenses the relative frequencies of the
main complications associated with each type of
procedure.
LATE OUTCOMES
Only a few valve-in-valve studies have reported 1-year
survival rates (10,56,57,59–65). The mean mortality
rate at 1 year has been 15.1% (ranging from0% to 16.8%)
(Table 2). Factors associated with increased 1-year
mortality were smaller surgical valves, stenosis as a
mechanism of valve dysfunction, and use of the tran-
spical approach (Figure 7) (10). No cases of structural
valve failure at midterm follow-up were reported in
the most important series of valve-in-valve pro-
cedures, but further studies with a longer-term follow-
up are needed to determine the degeneration rate of
transcatheter valves following these procedures.
MITRAL VALVE-IN-VALVE AND
VALVE-IN-RING PROCEDURES
Perioperative mortality and morbidity exceeds 15% in
patients >75 years of age after reoperation following a
ﬁrst mitral valve intervention (67). Transcatheter
valve-in-valve implantation, and, more recently,
valve-in-ring procedures have emerged as less inva-
sive alternatives to redo open heart surgery in selected
patients deemed at high surgical risk. However, it
should be stressed that these new procedures are
performedwith devices thatwere initially designed for
the aortic or pulmonary valve. Therefore, they are still
considered “off-label” and should be performed only
as a last resort, when no other feasible options exist.
PRE-PROCEDURAL WORK-UP AND PROCEDURAL
ASPECTS. Similar to aortic valve-in-valve pro-
cedures, an accurate knowledge of the surgical mitral
TABLE 2 Published Case Series (>10 Patients) on Aortic Valve-in-Valve Procedures
First Author,
Year (Ref. #) N THV Approach
Age
(yrs)
Bioprosthesis
Failure
AR/AS/Mixed
(%)
Logistic
EuroSCORE
(%)
STS
Score
(%)
LVEF
(%)
Procedural
Success
(%)
Mean
Gradient
Post-ViV
(mm Hg)
AR >
Moderate Pacemaker
THV
Malposition
(%)
Coronary
Obstruction
(%)
PPM
(%)
Mortality
at 30 days
(%)
Mortality
at 1 yr
(%)
Kempfert et al.,
2010 (56)
11 SAPIEN TA 78 73/0/27 31.7 7.2 53.8 100 11 0 0 NR NR NR 0 0
Webb et al.,
2010 (36)
10 SAPIEN TA/TF 82.1 50/10/40 30.4 10 55 100 12.8 0 0 10 NR NR 0 NR
Pasic et al.,
2011 (57)
14 SAPIEN TA 73.3 NR 45.3 21.9 45 100 13.1 0 0 0 0 NR 0 14.3
Eggebrecht et al.,
2011 (58)
47 SAPIEN/
CoreValve
TA/TF 79.8 47/32/21 35 11.6 52 98 17 2 NR 8 NR NR 17 NR
Bedogni et al.,
2011 (59)
25 CoreValve TF/TAx 82.4 36/64/0 31.5 8.2 56.5 100 13.8 0 12 NR 8 NR 12 16
Bapat et al.,
2012 (60)
23 SAPIEN TA/TF 76.9 61/39/0 31.8 7.6 48 100 9.1 0 0 4.3 0 NR 0 12.5
Seiffert et al.,
2012 (61)
11 SAPIEN TA 79.3 36/36/27 31.8 12.5 50.1 100 17.9 0 NR NR NR 45.45 NR 16.6
Latib et al.,
2012 (62)
18 SAPIEN TF/TA/
TAx
75 33/50/17 37.4 8.2 52.9 94 12.4 0 11.7 NR 0 NR 0 5.6
Linke et al.,
2012 (63)
27 CoreValve TF 74.8 22/7/71 31.3 NR NR 100 18 7.4 3.7 3.7 0 NR 7.4 12
Gaia et al.,
2012 (34)
14 Braile Inovare TA 69.8 NR 42.9 38.6 51 100 12.8 NR NR NR NR NR 14.3 NR
Dvir et al.,
2014 (10)
459 CoreValve/
SAPIEN
TA/TF/
TAO/
TAx
77.6 39/30/30 31.1 9.8 50.3 93.1 15.8 5.4 8.3 15.3 2 31.8 7.6 16.8
Ihlberg et al.,
2013 (64)
45 CoreValve/
SAPIEN
TA/TF 80.6 51/29/18 NR 14.6 46.3 95.6 16.4 2 7 2.2 0 NR 4.4 11.9
Subban et al.,
2014 (65)
12 SAPIEN/
CoreValve
TF/TS/TA/
TAO
78.5 50/50 NR 7.4 NR 100 15 8.3 16.6 8.3 0 33 0 0
Camboni et al.,
2015 (66)
31 SAPIEN/
CoreValve/
others
TA/TF 77.8 22/39/39 NR 20.9 55.6 88 16.1 NR 6 NR 10 NR 22.5 NR
AR ¼ aortic regurgitation; AS ¼ aortic stenosis; LVEF ¼ left ventricular ejection fraction; NR ¼ not reported; PPM ¼ prosthesis-patient mismatch; STS ¼ Society of Thoracic Surgeons; TA ¼ transapical; TAO ¼ transaortic; TAx ¼ transaxillary; TF ¼ transfemoral;
THV ¼ trancatheter heart valve; TS ¼ transseptal; ViV ¼ valve-in-valve.
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FIGURE 5 Incidence of Severe PPM After Valve-in-Valve Procedures
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Incidence of severe prosthesis-patient mismatch (PPM) following aortic valve-in-valve pro-
cedures, according to valve type (A) and the main mechanism of surgical valve failure (B) (10).
FIGURE 6 Rate of High Transvalvular Gradients Following
Aortic Valve-in-Valve Procedures
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Rate of transvalvular gradients $20 mm Hg following aortic valve-in-valve procedures,
according to surgical bioprosthesis size (10).
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2030prosthesis or ring is essential for planning a mitral
valve-in-valve or valve-in-ring procedure. The main
characteristics of the SHV have already been outlined
in a prior section of this review. Regarding the mitral
rings, the D-shape of the annuloplasty ring may result
in the occurrence of paravalvular leaks following
transcatheter valve implantation. Because ring cir-
cularization is important to ensure efﬁcient sealing,
a transcatheter valve-in-ring procedure should, per-
haps, be limited to deformable complete and rigid
semilunar annuloplasty devices. Table 4 summarizes
all the known surgical mitral rings amenable to a
valve-in-ring procedure. Selection of the most ap-
propriate THV is critical. Indeed, especially during
valve-in-ring procedures, the capability of the THV
to assume a D-shaped morphology, if needed, (e.g.,
Direct Flow valve) could become an important asset.
PRE-PROCEDURAL CONSIDERATIONS. Akin to aortic
valve procedures, patients should undergo a multi-
disciplinary team evaluation including cardiologists,
cardiothoracic surgeons, anesthesiologists, nurses,
and geriatricians. Transthoracic echocardiography
and TEE should be performed to assess the
severity and mode of bioprosthetic mitral valve fail-
ure, as well as left ventricular function. Concomitant
coronary disease should be ruled out by a coronary
angiogram before the procedure. CT is also very
useful to provide information on valve dimensions
and other geometric considerations. Left ventricular
outﬂow tract (LVOT) obstruction is one of the po-
tential complications of mitral transcatheter valve
procedures, and the proximity between the surgical
valve and LVOT, as well as LVOT dimensions should
be assessed. However, the exact role of CT measure-
ments in pre-procedural planning needs to be further
evaluated (e.g., to better predict the risk of LVOT
obstruction).
VALVE SIZING. To optimize anchoring and to limit
paravalvular leakage, a minimum of 10% oversizing of
the transcatheter valve compared with the true in-
ternal diameter of the surgical device is currently
recommended (68). It is not appropriate to perform
extreme oversizing, as a signiﬁcantly underexpanded
transcatheter valve may lead to incorrect leaﬂet
coaptation, elevated transvalvular gradient, and
limited durability.
APPROACH. The majority of mitral valve-in-valve
cases are performed within a dedicated hybrid the-
ater or in an operating room under general anes-
thesia. When the transapical approach is selected, a
left mini-thoracotomy is used and purse-string su-
tures reinforced with pledgets are prepared. The left
ventricular apex is punctured, the access sheath is
FIGURE 7 Mortality Rates at 1-Year Follow-Up After Aortic Valve-in-Valve Procedures
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Mortality rates following aortic valve-in-valve procedures, according to the main mecha-
nism of surgical valve dysfunction (A), surgical valve size (B), and type of transcatheter
valve (C). Reprinted with permission from Dvir et al. (10).
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2031inserted inside the left ventricle, and a guidewire is
advanced under ﬂuoroscopy across the failing bio-
prosthetic mitral valve into a pulmonary vein. The
wire is then exchanged for a stiffer wire. The trans-
catheter valve (which is crimped in a reverse fashion
when an Edwards SAPIEN is used) is then delivered
through a standard delivery system. The trans-
catheter valve is implanted with ﬂuoroscopic and TEE
guidance, during rapid ventricular pacing.
When the transseptal approach is chosen, femoral
or jugular venous access is obtained. A transseptal
puncture is done in a high and posterior position.
After placing a sheath in the left atrium, a bolus of
heparin is administered and a guidewire is positioned
in the left ventricle. Afterward, a stiffer wire with a J
curve at the end is gently placed at the left ventricular
apex. Pre-dilation is generally avoided. Then, the
valve, mounted for an antegrade implantation, is
advanced across the atrial septum and then implan-
ted using a slow balloon inﬂation technique, under
rapid ventricular pacing.
VALVE POSITIONING. The transcatheter valve should
be positioned 3 to 5 mm atrially, relative to the sewing
cuff of the SHV (69). For mitral valve-in-ring pro-
cedures, it is generally recommended to center the
transcatheter valve in relation to the ring, with equal
portions within the left atrium and the left ventricle
(70). Examples of valve-in-valve and valve-in-ring
procedures are shown in Figure 8.
MITRAL VALVE-IN-VALVE AND
VALVE-IN-RING RESULTS
The reported results of the case series of mitral
valve-in-valve and valve-in-ring published to date
(43,44,68,70–76) are shown in Table 5. A total of 113
patients (77 valve-in-valve, 36 valve-in-ring) have
been reported, with a mean age of 72 years, and a
very high surgical risk proﬁle (mean logistic Euro-
score and STS scores of 40% and 13.8%, respec-
tively). Most procedures (64%) were performed via a
transapical approach and 36% of cases were per-
formed via a transseptal approach. The Edwards
SAPIEN XT valve was used in most cases (83%), and
the Melody valve was used in 12% of patients. The
transcatheter valve was successfully implanted in
94.5% of cases, and mean 30-day mortality rate was
8.2% (Central Illustration). LVOT obstruction
occurred in 8.3% of patients undergoing valve-in-
ring implantation (n ¼ 3), with no reported cases
in valve-in-valve procedures. Mean transvalvular
gradient post-valve implantation was 6.3 mm Hg and
TABLE 4 Surgical Mitral Rings Within Which
Transcatheter Heart Valves Have Been Implanted
Complete rings and band
Edwards Physio I/II
Medtronic Duran
St. Jude Seguin
Sorin Carbomedics
Medtronic Proﬁle 3D
Incomplete rings and bands
Edwards Classic
Cosgrove-Edwards Band
TABLE 3 Main Complications Associated With
Aortic Valve-in-Valve Procedures and Conventional TAVR
Complications Valve-in-Valve
Conventional
TAVR
Elevated post-procedural
gradients
þþþ þ
Coronary obstruction þþþ þ
Malpositioning þþ þ
Vascular complications þþ þþ
Permanent pacemaker þ þþ
Paravalvular leak  þþ
Annulus rupture  þ
TAVR ¼ transcatheter aortic valve replacement.
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2032residual leaks of at least moderate degree were
observed in 3.5% of patients.
The results of a retrospective collection of data
from multiple centers worldwide were recently pre-
sented (45). This study included a total of 349 and 88
patients who underwent a mitral valve-in-valve and
valve-in-ring procedure, respectively. The access
route was transapical (78.9%), transseptal afterFIGURE 8 Examples of Mitral Valve-in-Valve and Valve-in-Ring Proc
(A) Fluoroscopic image of a 28-mm Edwards Physio 1 ring (Edwards Lif
implantation of a 23-mm Edwards Sapien XT transcatheter heart valve i
(C) Fluoroscopic image of a failing 23-mm Mosaic valve (Medtronic, Min
ﬂuoroscopic image showing a 23-mm Edwards Sapien XT transcatheterjugular or femoral venous access (18.5%), and direct
left atrium (2.5%). The mean age of the study popu-
lation was 74 years, with 60% women, and a mean
STS score of 12.9%. The mechanisms of failure were
regurgitation, stenosis, and combined mode in 45%,
23%, and 32% of patients, respectively. The vast ma-
jority of the mitral procedures were done under
general anesthesia (98.9%) and a balloon pre-dilation
was performed in only 24% of cases. Malpositioning
of the transcatheter valve occurred in 6.6% of casesedures
esciences, Irvine, California). (B) Final ﬂuoroscopic image after the
nside the ring (valve-in-ring procedure) via a transapical approach.
neapolis, Minnesota) in the mitral position. (D) Post-procedural
heart valve implanted within the SHV through a transapical route.
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2033and LVOT obstruction in 6.9% of cases (2.6% and 8%
in valve-in-valve and valve-in-ring procedures,
respectively; p ¼ 0.03). At 30 days, the rate of all-
cause death was 8.5% (7.7% and 11.4% in valve-in-
valve and valve-in-ring procedures, respectively;
p ¼ 0.15) and the occurrence of stroke was 2.5% (2.9%
and 1.1% in valve-in-valve and valve-in-ring pro-
cedures, respectively; p ¼ 0.33). The main procedural
results according to the type of procedure (valve-in-
valve vs. valve-in-ring) are summarized in Figure 9.
Predictors of suboptimal valve hemodynamic re-
sults were also evaluated. The main predictor of post-
procedural elevated mitral gradients ($10 mm Hg)
was the presence of a small surgical valve size (label
size #25 mm). Signiﬁcant residual mitral regurgita-
tion ($moderate) was more frequent after mitral
valve-in-ring than after valve-in-valve procedures
(14.8% vs. 2.6%; p < 0.001) (Figure 9).
The late results (>3 months) of valve-in-valve and
valve-in-ring procedures are limited to 7 reports,
including a total of 93 patients (43,68,70,71,73,75,76).
The mortality rate after a mean follow-up of 14
months was 20.5%. Four cases of valve thrombosis
were reported, all >30 days after a valve-in-valve
procedure (70,74). During follow-up, 1 patient un-
derwent a second transapical valve-in-valve implan-
tation due to transcatheter valve migration 2 months
after an uneventful valve-in-valve procedure (68).
There were no cases of late structural valve failure
requiring reintervention.
In summary, the preliminary experience with
mitral valve-in-valve and valve-in-ring procedures
has outlined its feasibility, with acceptable clinical
and hemodynamic 30-day and late results, despite
the high-risk proﬁle of the treated population.
Most procedures were performed via a transapical
approach, which is more invasive, yet more direct,
and an easier approach for such procedures. Howev-
er, a progressive shift towards a higher use of
the transfemoral/transseptal approach is likely to be
seen in the coming years. Of note, valve-in-ring pro-
cedures were associated with a much higher risk of
major complications, including a higher rate of re-
sidual regurgitation and LVOT obstruction. A better
understanding of the ring characteristics leading to
these greater failure rates is required. Preliminary
data suggests that subacute or late valve thrombosis
rates may be more frequent in transcatheter valves
positioned within the mitral (vs. aortic) position,
further outlining that anticoagulation therapy
following these procedures may be the preferred
antithrombotic strategy. Finally, close clinical follow-
up of these patients will be required to determine
valve durability and potential late complications.
FIGURE 9 30-Day Outcomes After Mitral Valve-in-Valve and
Mitral Valve-in-Ring Procedures
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Thirty-day rates of death, major stroke, mitral regurgitation $ moderate (MR), and left
ventricular outﬂow tract (LVOT) obstruction following transcatheter mitral valve-in-valve
(n ¼ 349) and valve-in-ring (n ¼ 88) procedures (45).
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2034VALVE-IN-VALVE PROCEDURES:
UNRESOLVED ISSUES AND FUTURE DIRECTIONS
The valve-in-valve proof-of-concept described by
Walther et al. (9) in 2007 heralded a new era of
transcatheter-based heart valve therapies. Since
then, due to its less invasive and appealing nature to
both patients and physicians alike, when compared
with redo open-heart surgery, valve-in-valve proce-
dure rates continue to grow rapidly. Nonetheless,
aortic valve-in-valve procedures still include several
safety concerns, such as a higher rate of valve mal-
positioning (especially in cases of stentless valves,
with aortic regurgitation as the main mechanism of
failure), coronary obstruction, and elevated trans-
valvular gradients (particularly in smaller surgical
valves). The arrival of newer-generation transca-
theter valves with repositionability and retrievability
properties should reduce the incidence of some of
these complications. Also, nonrandomized data sug-
gest a valve-type effect inﬂuencing the hemodynamic
results of valve-in-valve procedures, with a supra-
annular valve leaﬂet position within the trans-
catheter valve stent frame serving as an important
factor determining improved hemodynamics (i.e.,
lower residual transvalvular gradients). One could
therefore postulate that the optimal design forfuture transcatheter devices for valve-in-valve pro-
cedures should contain: 1) a thin stent frame struc-
ture, probably without any bulky additional
antiparavalvular leak features that could increase
transvalvular gradients post-procedure; 2) reposi-
tionability and retrievability properties; 3) a mecha-
nism for grasping the surgical valve leaﬂets in order
to avoid coronary obstruction; and 4) a supra-annular
position of the valve leaﬂets within the stent frame,
in order to improve valve hemodynamics.
Whereas data on long-term (up to 5 years) THV
durability following standard (for native valves)
TAVR procedures is promising (77), there are scarce
data on long-term durability of transcatheter valves
following valve-in-valve procedures (68,78). Howev-
er, it appears conceivable to anticipate a reduction in
valve durability in the setting of valve-in-valve pro-
cedures, especially in cases of elevated gradients and
when underexpansion is substantial (79).
For mitral valve-in-valve and valve-in-ring pro-
cedures, the risk of LVOT obstruction, valve throm-
bosis, and unknown durability are some of the
unresolved issues linked with such procedures. In
addition, both the best antithrombotic regime and
the speciﬁc anatomic and patient characteristics in-
creasing the risk of a mitral transcatheter procedure
are yet to be determined.
Although we recognize the current limitations of
valve-in-valve procedures, the growth of this tech-
nology in the near future is inevitable. It is therefore
conceivable that the selection of valve type and
technique during SAVR could be inﬂuenced by the
convenience of a transcatheter valve-in-valve tech-
nique at a later time period. In younger individuals
undergoing SAVR, the future availability of less
invasive procedural options to treat structural valve
failure could become an argument in favor of im-
planting a surgical tissue valve. Moreover, during
the index surgical procedure, the beneﬁts of annular
enlargement or other techniques to obtain the lar-
gest effective oriﬁce area possible may be consi-
dered in order to avoid PPM post-surgery. This
will also enable enhanced optimization of potential
future valve-in-valve procedures, should the sur-
gical valve ultimately fail. Also, aortic SHVs which
carry an increased risk for coronary obstruction
post-transcatheter valve-in-valve therapy may be
implanted less frequently, considering the risk of
future bioprosthetic valve failure and the potential
requirement for a valve-in-valve procedure. Bearing
in mind preliminary data suggesting the lower mor-
tality rate after valve-in-valve procedures when the
major mode of failure of tissue valves is regurgita-
tion, the treatment paradigm shift in SAVR may also
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2035include a greater implantation rate of SHVs with
regurgitation as the predicted main mechanism of
degeneration.
Even if current data supports the use of valve-in-
valve procedures for most patients, a thorough
multidisciplinary heart team approach is strongly
recommended for every patient considered for this
type of transcatheter therapy. Long-term follow-up
and increasing the worldwide clinical experience will
be fundamental for establishing the exact role ofvalve-in-valve implantation for treating degenerative
bioprosthetic valves, as well as for addressing the
numerous knowledge gaps associated with these
innovative procedures.
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